Publications

  1. Taylor G, Karlin N, Halfdanarson TR, Coppola K, Grothey A. Leptomeningeal Carcinomatosis in Colorectal Cancer: The Mayo Clinic Experience. Clin Colorectal Cancer. 2017 Nov 21 [Epub ahead of print]
    View PubMed
  2. Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer; A JSMO - ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2017 Nov 16 [Epub ahead of print]
    View PubMed
  3. Ahn DH, Grothey A. Continued disappointments with targeted agents in first-line therapy of advanced gastric cancers. Lancet Oncol. 2017 Nov; 18 (11):1427-1428 Epub 2017 Sept 25
    View PubMed
  4. Grothey A, Strosberg JR, Renfro LA, Hurwitz HI, Marshall J, Safran H, Guarino MJ, Kim GP, Hecht JR, Weil SC, Heyburn J, Wang W, Schweizer C, O'Shannessy DJ, Diaz LA. A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Ontuxizumab (MORAb-004) in Patients with Chemorefractory Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Oct 30 [Epub ahead of print]
    View PubMed
  5. Witzig TE, Johnston PB, LaPlant BR, Kurtin PJ, Pederson LD, Moore DF Jr, Nabbout NH, Nikcevich DA, Rowland KM, Grothey A. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). Am J Hematol. 2017 Oct; 92 (10):1004-1010 Epub 2017 Aug 17
    View PubMed
  6. Johnson B, Jin Z, Truty MJ, Smoot RL, Nagorney DM, Kendrick ML, Kipp BR, Grothey A. Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist. 2017 Sep 13 Epub 2017 Sept 13
    View PubMed
  7. McCleary NJ, Hubbard J, Mahoney MR, Meyerhardt JA, Sargent D, Venook A, Grothey A. Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol. 2017 Sep 13 Epub 2017 Sept 13
    View PubMed
  8. Jones JC, Renfro LA, Al-Shamsi HO, Schrock AB, Rankin A, Zhang BY, Kasi PM, Voss JS, Leal AD, Sun J, Ross J, Ali SM, Hubbard JM, Kipp BR, McWilliams RR, Kopetz S, Wolff RA, Grothey A. Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017 Aug 10; 35 (23):2624-2630 Epub 2017 May 09
    View PubMed
  9. Nelson H, Machairas N, Grothey A. Evidence in Favor of Standard Surgical Treatment for Rectal Cancer. JAMA Oncol. 2017 Jul 01; 3: (7)885-886.
    View PubMed
  10. Hubbard JM, Grothey A. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor. Drugs. 2017 Jul; 77 (10):1091-1103
    View PubMed
  11. Renfro LA, Goldberg RM, Grothey A, Sobrero A, Adams R, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Hoff PM, Kabbinavar FF, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Souglakos J, Bokemeyer C, Van Cutsem E, Saltz L, de Gramont A, Sargent DJ, ARCAD Clinical Trials Program. Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancerologie Digestive Database. J Clin Oncol. 2017 Jun 10; 35 (17):1929-1937 Epub 2017 Apr 17
    View PubMed
  12. Zhang BY, Jones JC, Briggler AM, Hubbard JM, Kipp BR, Sargent DJ, Dixon JG, Grothey A. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2017 Jun; 16: (2)124-128.
    View PubMed
  13. Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Mar; 15: (3)370-398.
    View PubMed
  14. Riechelmann R, Grothey A. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol. 2017 Feb; 9 (2):106-126 Epub 2016 Nov 10
    View PubMed
  15. Gonzalez JM, Ogale S, Morlock R, Posner J, Hauber B, Sommer N, Grothey A. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment. Cancer Manag Res. 2017; 9:149-158.
    View PubMed
  16. Childs DS, Jacobson AC, Mitchell JL, Hubbard JM, Yoon HH, Finnes H, Grothey A, Jatoi A. Prescriber adherence to antiemetic guidelines with the new agent trifuridine-tipiracil Journal of Community and Supportive Oncology. 2017; 15: (3)e142-6.
  17. Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, Ruddy KJ, Lafky JM, Ta LE, Beutler AS, Wagner-Johnston ND, Staff NP, Grothey A, Dougherty PM, Cavaletti G, Loprinzi CL. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer. 2016 Dec; 24 (12):5059-5068 Epub 2016 Aug 18
    View PubMed
  18. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A, Analysis and Research in Cancers of the Digestive System (ARCAD) Group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016 Dec; 17 (12):1709-1719 Epub 2016 Oct 12
    View PubMed
  19. Singh PP, Shi Q, Foster NR, Grothey A, Nair SG, Chan E, Shields AF, Goldberg RM, Gill S, Kahlenberg MS, Sinicrope FA, Sargent DJ, Alberts SR. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist. 2016 Dec; 21 (12):1509-1521 Epub 2016 Nov 23
    View PubMed
  20. Mahipal A, Grothey A. Role of Biologics in First-Line Treatment of Colorectal Cancer. J Oncol Pract. 2016 Dec; 12 (12):1219-1228
    View PubMed
  21. Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the analysis and research in cancers of the digestive system (arcad) database Lancet Oncology. 2016 Dec; 17: (12)1709-19.
  22. Rankin A, Klempner SJ, Erlich R, Sun JX, Grothey A, Fakih M, George TJ Jr, Lee J, Ross JS, Stephens PJ, Miller VA, Ali SM, Schrock AB. Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. Oncologist. 2016 Sep 28 Epub 2016 Sept 28
    View PubMed
  23. Grothey A, Sargent DJ. Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine. JAMA Oncol. 2016 Sep 01; 2: (9)1133-4.
    View PubMed
  24. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Kohne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Osterlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taieb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug; 27: (8)1386-422.
    View PubMed
  25. Kasi PM, Kotani D, Cecchini M, Shitara K, Ohtsu A, Ramanathan RK, Hochster HS, Grothey A, Yoshino T. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study. BMC Cancer. 2016 Jul 13; 16:467 Epub 2016 July 13
    View PubMed
  26. Grothey A, Ellis LM. Therapy: Colorectal cancer: how to teach an old drug new tricks. Nat Rev Gastroenterol Hepatol 2016 Jul; 13 (7):384-5 Epub 2016 May 25
    View PubMed
  27. Thanarajasingam G, Atherton PJ, Novotny PJ, Loprinzi CL, Sloan JA, Grothey A. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol. 2016 May; 17 (5):663-70 Epub 2016 Apr 12
    View PubMed
  28. Kasi PM, Grothey A. Chemotherapy Maintenance. Cancer J. 2016 May-Jun; 22: (3)199-204.
    View PubMed
  29. Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ. Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database. J Clin Oncol. 2016 Apr 10; 34: (11)1182-9.
    View PubMed
  30. Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, Lafky JM, Qin R, Grothey A, Loprinzi CL. MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer. 2016 Mar; 24: (3)1071-8.
    View PubMed
  31. Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016 Mar; 26 (3):133-7
    View PubMed
  32. Grothey A. Optimal Use of Regorafenib: Dosing Strategies and Patient Selection. Clin Adv Hematol Oncol. 2016 Mar; 14: (3 Suppl 3)8-10.
    View PubMed
  33. Grothey A, Marshall JL, Seery TE. Current Options for Third-Line Treatment of Metastatic Colorectal Cancer. Clin Adv Hematol Oncol. 2016 Mar; 14: (3 Suppl 3)1-15.
    View PubMed
  34. Hubbard JM, Kim G, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Invest New Drugs. 2016 Feb; 34: (1)96-103.
    View PubMed
  35. Majithia N, Grothey A. Regorafenib in the treatment of colorectal cancer. Expert Opin Pharmacother. 2016; 17: (1)137-45.
    View PubMed
  36. Coutinho A, Grothey A, Marshall JL. Adjuvant therapy after resection of metastatic colorectal cancer Oncology (08909091). 2016; 30: (1)50-3.
  37. Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Osterlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Kohne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litiere S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Oberg K, Palumbo A, Peccatori FA, Pfeilstocker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016; 1 (5):e000097 Epub 2016 Sept 29
    View PubMed
  38. Grothey A, Marshall JL, Seery TE. Current options for third-line treatment of metastatic colorectal cancer: discussion Clinical Advances in Hematology and Oncology. 2016; 14: (3)13-4.
  39. Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argiles G, Adenis A, Ychou M, Barone C, Bouche O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S. Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). ESMO Open. 2016; 1 (6):e000111 Epub 2017 Feb 13
    View PubMed
  40. An MW, Dong X, Meyers J, Han Y, Grothey A, Bogaerts J, Sargent DJ, Mandrekar SJ, Response Evaluation Criteria in Solid Tumors Steering Committee. Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. J Natl Cancer Inst. 2015 Nov; 107: (11).
    View PubMed
  41. Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol. 2015 Oct 20; 33: (30)3416-22.
    View PubMed
  42. Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A. The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. J Natl Cancer Inst. 2015 Oct; 107: (10).
    View PubMed
  43. Hecht JR, Douillard JY, Schwartzberg L, Grothey A, Kopetz S, Rong A, Oliner KS, Sidhu R. Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treat Rev. 2015 Sep; 41 (8):653-9 Epub 2015 May 21
    View PubMed
  44. Pachman DR, Ruddy K, Sangaralingham LR, Grothey A, Shah ND, Beutler AS, Hubbard JM, Loprinzi CL. Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. J Natl Compr Canc Netw. 2015 Sep; 13: (9)1097-101.
    View PubMed
  45. Sargent DJ, Mandrekar S, Grothey A. Introduction to special issue on biomarker-based clinical trial designs in oncology. Chin Clin Oncol. 2015 Sep; 4: (3)28.
    View PubMed
  46. Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Yoshino T, Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol. 2015 Aug; 16 (8):937-48 Epub 2015 July 13
    View PubMed
  47. Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015 Jun; 13: (6)719-28; quiz 728.
    View PubMed
  48. Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, Hamada Y, Ohtsu A. Randomized phase iii trial of regorafenib in metastatic colorectal cancer: analysis of the correct japanese and non-japanese subpopulations. Invest New Drugs. 2015 Jun; 33(3):740-50.
    View PubMed
  49. Benson AB III, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Grothey A, Hochster HS, Hunt S, Kamel A, Kirilcuk N, Leong LA, Lin E, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass D. Rectal cancer, version 2.2015 featured updates to the nccn guidelines. J. Natl. Compr. Cancer Netw. 2015 Jun; 13(6):719-28.
  50. Renfro LA, Grothey A, Kerr D, Haller DG, Andre T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group . Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general populationdagger. Ann Oncol. 2015 May; 26: (5)950-8.
    View PubMed
  51. Grothey A. Optimizing systemic therapy selection in metastatic colorectal cancer. J Natl Compr Canc Netw. 2015 May; 13: (5 Suppl)682-5.
    View PubMed
  52. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausova J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F, RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May; 16: (5)499-508.
    View PubMed
  53. Phuoc V, Grothey A. Metastatic extramammary Paget's disease responding to weekly paclitaxel. BMJ Case Rep. 2015 Apr 22; 2015:
    View PubMed
  54. Hubbard JM, Grothey A. Colorectal cancer in 2014: progress in defining first-line and maintenance therapies. Nat Rev Clin Oncol. 2015 Feb; 12: (2)73-4.
    View PubMed
  55. Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJ, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Diaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J Clin Oncol. 2015 Jan 1; 33: (1)22-8.
    View PubMed
  56. Kasi PM, Thanarajasingam G, Finnes HD, Villasboas Bisneto JC, Hubbard JM, Grothey A. Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. Case Rep Oncol Med. 2015; 2015:420159.
    View PubMed
  57. Yan Y, Grothey A. Molecular profiling in the treatment of colorectal cancer: focus on regorafenib. Onco Targets Ther. 2015; 8:2949-57.
    View PubMed
  58. Liu H, Tan AD, Qin R, Sargent DJ, Grothey A, Buckner JC, Schaefer PL, Sloan JA. Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag. 2015; 2 (2) Epub 2015 Apr 10
    View PubMed
  59. Leal AD, Hubbard J, Sargent D, Grothey A. New adjuvant trial designs in colon cancer Current Colorectal Cancer Reports. 2015; 11: (6)326-34.
  60. Hubbard JM, Grothey A. Colorectal cancer in 2014 : Progress in defining first-line and maintenance therapies Nature Reviews Gastroenterology and Hepatology. 2015; 12: (1)19-20.
  61. Renfro LA, Grothey A, Xue Y, Saltz LB, Andre T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group . ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer. J Natl Cancer Inst. 2014 Dec; 106: (12)
    View PubMed
  62. Grothey A, Yoshino T, Xu R, Zalcberg J, Sargent DJ, Choti M, Rutstein M, Cupit L, Kuss I, Van Cutsem E. 611TiPADJUVANT REGORAFENIB (REG) IN STAGE IV COLORECTAL CANCER (CRC) AFTER CURATIVE TREATMENT OF LIVER METASTASES: A PHASE III RANDOMIZED, PLACEBO (PBO)-CONTROLLED TRIAL (COAST). Ann Oncol. 2014 Sep 01; 25: (suppl_4)iv208.
    View PubMed
  63. Schmoll H, Arnold D, De Gramont A, Ducreux M, Grothey A, O'Dwyer PJ, Tabernero J, Bendahmane B, Hermann F, Ingold C, Mancao C, Osborne S, Statovci I, Van Cutsem E. 612TiPMODUL-A MULTICENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN THERAPY FOR THE 1ST-LINE MAINTENANCE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): A SIGNAL-SEEKING APPROACH. Ann Oncol. 2014 Sep 01; 25: (suppl_4)iv209.
    View PubMed
  64. Grothey A, Arnold D, Van Cutsem E, Bekaii-Saab T, Kozloff M, Bennouna J, Revil C, Donica M, Sommer N, Leutgeb B, Ekstrand-Olsen M, Hermann F, Hurwitz H. 520POVERALL SURVIVAL ACCORDING TO PATIENT SUBGROUPS: RESULTS FROM A POOLED ANALYSIS OF 5 OBSERVATIONAL OR PHASE IV STUDIES OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER. Ann Oncol. 2014 Sep 01; 25: (suppl_4)iv176-iv177.
    View PubMed
  65. Sargent DJ, Paul J, Sobrero A, Andre T, Shields AF, Yoshino T, Souglakos I, Iveson T, Labianca R, Taieb J, Meyerhardt J, Ohtsu A, Grothey A. 609TiPTHE IDEA (INTERNATIONAL DURATION EVALUATION OF ADJUVANT CHEMOTHERAPY) COLLABORATION: A PROSPECTIVE POOLED NON-INFERIORITY ANALYSIS OF > 11,500 PATIENTS FROM 6 PHASE III TRIALS OF ADJUVANT THERAPY DURATION WITH FOLFOX (FOLFOX4 OR MFOLFOX6) OR XELOX (3 VS. 6 MONTHS) FOR STAGE III COLON CANCER. Ann Oncol. 2014 Sep 01; 25: (suppl_4)iv207-iv208.
    View PubMed
  66. Hubbard JM, Grothey AF, McWilliams RR, Buckner JC, Sloan JA. Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice. J Oncol Pract. 2014 Jul; 10: (4)248-53.
    View PubMed
  67. Grothey A, Flick ED, Cohn AL, Bekaii-Saab TS, Bendell JC, Kozloff M, Roach N, Mun Y, Fish S, Hurwitz HI. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf. 2014 Jul; 23: (7)726-34.
    View PubMed
  68. Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR, Alliance for Clinical Trials in Oncology. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst. 2014 Jul; 106 (7) Epub 2014 June 12
    View PubMed
  69. Huang J, Nair SG, Mahoney MR, Nelson GD, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Thibodeau SN, Smyrk TC, Grothey A, Sinicrope FA, Webb TA, Farr GH Jr, Pockaj BA, Berenberg JL, Mooney M, Sargent DJ, Alberts SR, Alliance for Clinical Trials in Oncology. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 2014 Jun; 13 (2):100-9 Epub 2013 Dec 28
    View PubMed
  70. Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014 Jun; 19: (6)669-80.
    View PubMed
  71. Hochster HS, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, Chowhan N, Ramanathan RK, Keaton M, Hainsworth JD, Childs BH. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol. 2014 Jun; 25: (6)1172-8.
    View PubMed
  72. Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A, ARIES Study Investigators. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin((R)) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol). 2014 Jun; 26: (6)323-32.
    View PubMed
  73. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CBAlliance). J Clin Oncol. 2014 Apr 01; 32: (10)997-1005.
    View PubMed
  74. Mandrekar SJ, An MW, Meyers J, Grothey A, Bogaerts J, Sargent DJ. Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse. J Clin Oncol. 2014 Mar 10; 32: (8)841-50.
    View PubMed
  75. Sridharan M, Hubbard J, Grothey A. Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions Oncology.2014;
  76. Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. Invest New Drugs. 2013 Dec; 31 (6):1559-67 Epub 2013 Oct 10
    View PubMed
  77. Shi Q, Andre T, Grothey A, Yothers G, Hamilton SR, Bot BM, Haller DG, Van Cutsem E, Twelves C, Benedetti JK, O'Connell MJ, Sargent DJ. Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. J Clin Oncol. 2013 Oct 10; 31: (29)3656-63.
    View PubMed
  78. Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression--implications for drug resistance. Nat Rev Clin Oncol. 2013 Oct; 10(10):571-87. Epub 2013 Sep 03.
    View PubMed
  79. Hubbard JM, Grothey A. Adolescent and young adult colorectal cancer. J Natl Compr Canc Netw. 2013 Oct 1; 11(10):1219-25.
    View PubMed
  80. Cheville AL, Kollasch J, Vandenberg J, Shen T, Grothey A, Gamble G, Basford JR. A home-based exercise program to improve function, fatigue, and sleep quality in patients with Stage IV lung and colorectal cancer: a randomized controlled trial. J Pain Symptom Manage. 2013 May; 45: (5)811-21.
    View PubMed
  81. Grothey A, Van Cutsem, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, CORRECT Study. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26; 381(9863):303-12. Epub 2012 Nov 22.
    View PubMed
  82. Clary BM, Grothey A, Kopetz S, Marsh RDW. Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: Expert consensus statement. HPB. 2013; 15(2):116-8.
    View PubMed
  83. Andre T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, Paul J, Sobrero A, Taieb J, Shields AF, Ohtsu A, Grothey A, Sargent DJ, for the IDEA Steering Committee. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Curr Colorectal Cancer Rep. 2013; 9:261-9.
    View PubMed
  84. Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012 Nov; 4: (6)301-19.
    View PubMed
  85. Warsame R, Grothey A. Treatment options for advanced pancreatic cancer: a review. Expert Rev Anticancer Ther. 2012 Oct; 12(10):1327-36.
    View PubMed
  86. Grothey A. Highlights in metastatic colorectal cancer from the 2012 American Society Of Clinical Oncology Annual Meeting. Clin Adv Hematol Oncol. 2012 Jul; 10(7 Suppl 9):1-24.
    View PubMed
  87. Di Valentin, Alam Y, Ali Alsharm, Arif S, Aubin F, Biagi J, Booth CM, Bourque S, Burkes R, Champion P, Colwell B, Cripps C, Dallaire M, Dorreen M, Finn N, Frechette D, Gallinger S, Gapski J, Giacomantonio C, Gill S, Goel R, Goodwin R, Grimard L, Grothey A, Hammad N, Hedley D, Jhaveri K, Jonker D, Ko Y, L'esperance M, Maroun J, Ostic H, Perrin N, Rother M, St-Hilaire E, Tehfe M, Thirlwell M, Welch S, Yarom N, Asmis T. Eastern Canadian colorectal cancer consensus conference: application of new modalities of staging and treatment of gastrointestinal cancers. Curr Oncol. 2012 Jun; 19(3):169-74.
    View PubMed
  88. Kabbinavar FF, Flynn PJ, Kozloff M, Ashby MA, Sing A, Barr CE, Grothey A. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012 May; 48(8):1126-32. Epub 2012 Mar 15.
    View PubMed
  89. Grothey A. Regorafenib in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2012 May; 10(5):324-5.
    View PubMed
  90. Alberts SR, Sargent DJ, Nair S, Mahoney MR, Mooney M, Thibodeau SN, Smyrk TC, Sinicrope FA, Chan E, Gill S, Kahlenberg MS, Shields AF, Quesenberry JT, Webb TA, Farr GH Jr, Pockaj BA, Grothey A, Goldberg RM. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012 Apr 4; 307 (13):1383-93
    View PubMed
  91. Polite BN, Sing A, Sargent DJ, Grothey A, Berlin J, Kozloff M, Feng S. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2012 Feb 15; 118(4):1083-90. Epub 2011 Jul 28.
    View PubMed
  92. Obholz K, Van Cutsem E, Press MF, Bowser A, Mortimer JA, Wasserstrom J, Grothey A. Effect of online education on use of molecular markers to guide treatment selection for advanced gastric or gastroesophageal (GE) cancer. J Clin Oncol. 2012 Feb; 30: (4_suppl)111.
    View PubMed
  93. McWilliams RR, Mahoney MR, Sargent DJ, Nelson GD, Sinicrope F, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Alberts SR. A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147. J Clin Oncol. 2012 Feb; 30: (4_suppl)446.
    View PubMed
  94. Bekaii-Saab TS, Grothey A, Bendell JC, Kozloff M, Cohn AL, Mun Y, Fish S, Flick ED, Dalal D, Hurwitz H. Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study. J Clin Oncol. 2012 Feb; 30: (4_suppl)535.
    View PubMed
  95. Grothey A, Sobrero AF, Siena S, Falcone A, Ychou M, Lenz HJ, Yoshino T, Cihon F, Wagner A, Van Cutsem E, CORRECT Study Team. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. J Clin Oncol. 2012 Feb; 30: (4_suppl)LBA385.
    View PubMed
  96. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20; 30(3):263-7. Epub 2011 Dec 12.
    View PubMed
  97. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res. 2012 Jan 15; 18: (2)546-54.
    View PubMed
  98. Grothey A. Optimal treatment strategies for localized and advanced microsatellite instability-high colorectal cancer. Current Colorectal Cancer Reports. 2012; 8(1):36-41.
  99. Lewis MA, Jaramillo S, Roberts L, Fleming CJ, Rubin J, Grothey A. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications. Oncologist. 2012; 17: (5)725-31.
    View PubMed
  100. Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012; 17: (12)1486-95.
    View PubMed
  101. Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, Speers C, Alberts SR, Bardia A, O'Connell MJ, Sargent DJ. Prognostic web-based models for stage II and III colon cancer: A population and clinical trials-based validation of numeracy and adjuvant! online. Cancer. 2011 Sep 15; 117(18):4155-65. Epub 2011 Mar 01.
    View PubMed
  102. Gonsalves WI, Grothey A. Waiting in line for cancer treatments? Gastrointest Cancer Res. 2011 Jul; 4(4):147-9.
    View PubMed
  103. Eadens MJ, Grothey A. Curable metastatic colorectal cancer. Curr Oncol Rep. 2011 Jun; 13 (3):168-76
    View PubMed
  104. Van Cutsem, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de, Zalcberg J. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol. 2011 Jun; 22 Suppl 5:v1-9.
    View PubMed
  105. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841. J Clin Oncol. 2011 May 20; 29: (15_suppl)3571.
    View PubMed
  106. Shi Q, Hubbard JM, Yothers GA, Andre T, Saltz L, Francini G, Bot BM, Twelves C, Buyse ME, Grothey A, Sargent DJ, ACCENT Collaborative Group. Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database. J Clin Oncol. 2011 May 20; 29: (15_suppl)3556.
    View PubMed
  107. Huang J, Sargent DJ, Mahoney MR, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Sinicrope F, Nair SG, Alberts SR. Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147. J Clin Oncol. 2011 May 20; 29: (15_suppl)3522.
    View PubMed
  108. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu T, Diasio RB, Jenkins RB, Sinicrope F. HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). J Clin Oncol. 2011 May 20; 29: (15_suppl)4012.
    View PubMed
  109. Jaramillo S, Lewis M, Roberts LR, Rubin J, Grothey A. Hospitalization after hepatic artery embolization (HAE) for neuroendocrine tumors (NET). J Clin Oncol. 2011 May 20; 29: (15_suppl)e14553.
    View PubMed
  110. Kozloff M, Bekaii-Saab TS, Bendell JC, Cohn AL, Hurwitz H, Roach N, Tezcan H, Fish S, Flick ED, Mun Y, Dalal D, Grothey A. Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS). J Clin Oncol. 2011 May 20; 29: (15_suppl)3625.
    View PubMed
  111. Alberts SR, Thibodeau SN, Sargent DJ, Mahoney MR, Sinicrope F, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Quesenberry JT, Smyrk TC, Grothey A, Nair SG. Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from NCCTG N0147. J Clin Oncol. 2011 May 20; 29: (15_suppl)3607.
    View PubMed
  112. Grothey A, Heun JM, Branda M, Goldberg RM, Sargent DJ. New lesions versus growth of existing disease: Does it impact prognosis? J Clin Oncol. 2011 May 20; 29: (15_suppl)2579.
    View PubMed
  113. Lafky JM, Bot BM, Morlan BW, Anderson SK, Kimlinger TK, Halling TM, Kumar S, Reynolds JT, Stella PJ, Dakhil SR, Loui WS, Alberts SR, Grothey A. Circulating endothelial cells (CECs) in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (BEV) and sorafenib. J Clin Oncol. 2011 May 20; 29: (15_suppl)e14063.
    View PubMed
  114. Palmer SR, Erlichman C, Fernandez-Zapico M, Qi Y, Almada L, McCleary-Wheeler A, Borad MJ, Molina JR, Grothey A, Pitot HC, Jatoi A, Northfelt DW, McWilliams RR, Okuno SH, Haluska P, Kim GP, Colon-Otero G. Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449. J Clin Oncol. 2011 May 20; 29: (15_suppl)3092.
    View PubMed
  115. Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A, Adjuvant Colon Cancer End-points (ACCENT) Group. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer. 2011 May; 47 (7):990-6 Epub 2011 Jan 21
    View PubMed
  116. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A. Integrating biomarkers in clinical trials. Expert Rev Mol Diagn. 2011 Mar; 11(2):171-82.
    View PubMed
  117. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Chitaley U, Alberts SR, Loprinzi CL. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011 Feb 01; 29: (4)421-7.
    View PubMed
  118. Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz H, Kozloff M, Tezcan H, Feng S, Flick ED, Sing A, Grothey A, ARIES Study Investigators. Similarities in treatment (Tx) patterns and clinical outcomes (CO) in patients (pts) with metastatic colorectal cancer (mCRC) initially treated with FOLFOX/BV or FOLFIRI/BV: Results from ARIES, a bevacizumab (BV) observational study. J Clin Oncol. 2011 Feb; 29: (4_suppl)480.
    View PubMed
  119. Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol. 2011; 5:89-99.
    View PubMed
  120. Heun JM, Grothey A, Branda ME, Goldberg RM, Sargent DJ. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. Oncologist. 2011; 16 (6):859-67 Epub 2011 May 31
    View PubMed
  121. Hubbard J, Grothey A. Reduced chemotherapy duration: A good idea? Current Colorectal Cancer Reports. 2011; 7(3):241-5.
  122. Blanke CD, Goldberg RM, Grothey A, Mooney M, Roach N, Saltz LB, Welch JJ, Wood WA, Meropol NJ. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist. 2011; 16(8):1061-8. Epub 2011 Jul 7.
    View PubMed
  123. Jordan K, Grothey A, Pelz T, Lautenschlager C, Franke U, Schober C, Schmoll HJ. Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting. Eur J Cancer Care (Engl). 2010 Sep; 19(5):603-9. Epub 2009 Aug 31.
    View PubMed
  124. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010 Jul 10; 28: (20)3219-26.
    View PubMed
  125. McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul 10; 28(20):3227-33. Epub 2010 Jun 07.
    View PubMed
  126. Hubbard J, Grothey A. Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol. 2010 Jul; 22(4):374-80.
    View PubMed
  127. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont. Biomarkers and surrogate end points--the challenge of statistical validation. Nat Rev Clin Oncol. 2010 Jun; 7(6):309-17. Epub 2010 Apr 6.
    View PubMed
  128. Gan HK, Grothey A, Pond GR, Moore MJ, Siu LL, Sargent D. Randomized phase II trials: inevitable or inadvisable? J Clin Oncol. 2010 May 20; 28(15):2641-7. Epub 2010 Apr 20.
    View PubMed
  129. Tang H, Foster NR, Grothey A, Ansell SM, Goldberg RM, Sargent DJ. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol. 2010 Apr 10; 28: (11)1936-41.
    View PubMed
  130. Halfdanarson TR, Kendrick ML, Grothey A. The role of chemotherapy in managing patients with resectable liver metastases. Cancer J. 2010 Mar-Apr; 16(2):125-31.
    View PubMed
  131. Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S, Sargent D. Adjuvant chemotherapy for resected stage II and III colon cancer: comparison of two widely used prognostic calculators. Semin Oncol. 2010 Feb; 37(1):39-46.
    View PubMed
  132. de Gramont, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010 Jan 20; 28(3):460-5. Epub 2009 Dec 14.
    View PubMed
  133. Grothey A. Risk assessment in stage II colon cancer: to treat or not to treat? Oncology (Williston Park). 2010 Jan; 24(1 Suppl 1):1-2.
    View PubMed
  134. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010; (3).
    View PubMed
  135. Bennett GJ, Grothey A, Loprinzi CL. Peripheral neurotoxicities. J Support Oncol. 2010; 8(2, suppl 1):22-3.
    View PubMed
  136. Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010; 78(5-6):329-39. Epub 2010 Aug 20.
    View PubMed
  137. Grothey A. My take: 'Remarkable' results present a quandary. Oncol. Rep.. 2010; (Jul-Aug)17.
  138. Van Cutsem, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, Van de, Schmoll HJ, Sobrero A, Tabernero J. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol. 2010; 21(Suppl 6):1-10.
  139. Grothey A. Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer. Oncology. 2010; 79(5-6):389-99. Epub 2011 Mar 25.
    View PubMed
  140. Hubbard J, Grothey A. Strategies for managing chemotherapy-induced sensory neuropathy. Current Colorectal Cancer Reports. 2010; 6(3):126-32.
  141. Banck MS, Grothey A. Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2009 Dec 15; 15(24):7492-501.
    View PubMed
  142. Seliger G, Mueller LP, Kegel T, Kantelhardt EJ, Grothey A, Groe R, Strauss HG, Koelbl H, Thomssen C, Schmoll HJ. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. Int J Gynecol Cancer. 2009 Nov; 19(8):1446-53.
    View PubMed
  143. Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol. 2009 Sep; 6: (9)507-18.
    View PubMed
  144. Grothey A. Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol. 2009 Sep; 1: (2)55-68.
    View PubMed
  145. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A, Investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009 Sep; 14(9):862-70. Epub 2009 Sep 2
    View PubMed
  146. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 1; 27(22):3677-83. Epub 2009 May 26.
    View PubMed
  147. Grothey A, Nikcevich DA, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Windschilt HE, Zhao X, Loprinzi CL. Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial. J Clin Oncol. 2009 May 20; 27: (15_suppl)4025.
    View PubMed
  148. Love N, Ault Ziel K, Bylund C, Elder M, Ellis LM, Grothey A, Meropol NJ, Paley D, Ravdin PM, Saltz LB. Adjuvant therapy report card: Patients with stage II/III colon cancer grade their oncologists. J Clin Oncol. 2009 May 20; 27: (15_suppl)4045.
    View PubMed
  149. Gill S, Loprinzi C, Kennecke H, Grothey A, Nelson G, Woods R, Speers C, Alberts S, Bardia A, Sargent D. Analysis of prognostic (prog) Web-based models for stage II and III colon cancer (CC): A population-based validation of Numeracy (NUM) and ADJUVANT! Online (ADJ!). J Clin Oncol. 2009 May 20; 27: (15_suppl)4044.
    View PubMed
  150. Costello BA, Hecht JR, Grothey A. Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review. J Clin Oncol. 2009 May 20; 27: (15_suppl)4054.
    View PubMed
  151. Liu H, Sloan JA, Sargent DJ, Satele DV, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Buckner JC. Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients. J Clin Oncol. 2009 May 20; 27: (15_suppl)9563.
    View PubMed
  152. Sloan JA, Liu H, Sargent DJ, Satele D, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Loprinzi CL, Buckner JC. A patient-level pooled analysis of the prognostic significance of baseline fatigue for overall survival (OS) among 3,915 patients participating in 43 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials. J Clin Oncol. 2009 May 20; 27: (15_suppl)9599.
    View PubMed
  153. Tang H, Foster NR, Grothey A, Ansell SM, Sargent DJ. Excessive false-positive errors in single-arm phase II trials: A simulation-based analysis. J Clin Oncol. 2009 May 20; 27: (15_suppl)6512.
    View PubMed
  154. Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Patiyil S, Thome S, Gill S, Sargent D. Adjuvant chemotherapy for resected stage II and III colon cancer: Comparison of widely used two prognostic calculators. J Clin Oncol. 2009 May 20; 27: (15_suppl)e15031.
    View PubMed
  155. Sargent DJ, Kohne CH, Sanoff HK, Bot BM, Seymour MT, de Gramont A, Porschen R, Saltz LB, Rougier P, Tournigand C, Douillard JY, Stephens RJ, Grothey A, Goldberg RM. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol. 2009 Apr 20; 27 (12):1948-55 Epub 2009 Mar 02
    View PubMed
  156. Sargent D, Sobrero A, Grothey A, O'Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O'Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009 Feb 20; 27: (6)872-7.
    View PubMed
  157. Wagner ADADW, Arnold D, Grothey AAG, Haerting J, Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer (Review) - art. no. CD005392. Cochrane Database Syst Rev. 2009; (3):5392.
    View PubMed
  158. Grothey A. Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial. Current Colorectal Cancer Reports. 2009; 5(2):65-6.
  159. Turja J, Grothey A. Individualizing therapy for metastatic colorectal cancer. Oncology (Williston Park). 2008 Nov 30; 22(13):1479-81.
    View PubMed
  160. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008 Nov 20; 26(33):5326-34. Epub 2008 Oct 14.
    View PubMed
  161. Grothey A. Surrogate endpoints for overall survival in early colorectal cancer from the clinician's perspective. Stat Methods Med Res. 2008 Oct; 17(5):529-35. Epub 2008 Feb 19.
    View PubMed
  162. Grothey A, Adjei AA, Alberts SR, Perez EA, Jaeckle KA, Loprinzi CL, Sargent DJ, Sloan JA, Buckner JC, North Central. North Central Cancer Treatment Group--achievements and perspectives. Semin Oncol. 2008 Oct; 35(5):530-44.
    View PubMed
  163. Grothey A. Improving the Odds for a Patient With Potentially Curable Stage IV Colorectal Cancer: A Question of Chemosensitivity. Gastrointest Cancer Res. 2008 Sep; 2(5):258-60.
    View PubMed
  164. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008 Jul; 44(11):1507-15. Epub 2008 Jun 18.
    View PubMed
  165. Kim GP, Grothey A. Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. Biologics. 2008 Jun; 2(2):223-8.
    View PubMed
  166. Liu H, Tan AD, Grothey A, Schaefer PL, Buckner JC, Loprinzi CL, Morton RF, Sloan JA. Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: A pooled analysis of 2,440 patients (pts). J Clin Oncol. 2008 May 20; 26: (15_suppl)9534.
    View PubMed
  167. Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS. Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): Final results of the phase III CONcePT trial. J Clin Oncol. 2008 May 20; 26: (15_suppl)4010.
    View PubMed
  168. Turja JH, Grothey A, Sargent DJ, Szydlo DW, Zhao X, Campbell ME, Goldberg RM, Sloan JA. Use of baseline quality of life (QOL) as compared with performance status (PS) as prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2008 May 20; 26: (15_suppl)4016.
    View PubMed
  169. Sloan JA, Grothey A, Green E, Zhao X, Campbell ME, Szydlo DW, Sargent DJ, Goldberg RM. Tumor burden is not related to quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 20; 26: (15_suppl)4017.
    View PubMed
  170. Sargent DJ, Marsoni S, Thibodeau SN, Labianca R, Hamilton SR, Torri V, Monges G, Ribic C, Grothey A, Gallinger S. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol. 2008 May 20; 26: (15_suppl)4008.
    View PubMed
  171. Nikcevich DA, Grothey A, Sloan JA, Kugler JW, Silberstein PT, Dentchev T, Wender DB, Novotny PJ, Windschitl HE, Loprinzi CL. Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7. J Clin Oncol. 2008 May 20; 26: (15_suppl)4009.
    View PubMed
  172. Kozloff MF, Sugrue MM, Purdie DM, Berlin JD, Flynn PJ, Kabbinavar FF, Sargent DJ, Dong W, Grothey A. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study. J Clin Oncol. 2008 May 20; 26: (15_suppl)4026.
    View PubMed
  173. Porschen R, Arkenau H, Arnold D, Cassidy J, Diaz-Rubio E, Douillard J, Grothey A, Hinke A, Schmiegel W, Schmoll H. Capecitabine and oxaliplatin as first-line treatment in patients with metastatic colorectal cancer (MCRC): A pooled analysis of randomized phase II-III trials. J Clin Oncol. 2008 May 20; 26: (15_suppl)4055.
    View PubMed
  174. Wagner AD, Arnold D, Grothey A, Haerting J, Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer (MCRC): Preliminary results of a systematic review and meta-analysis. J Clin Oncol. 2008 May 20; 26: (15_suppl)4060.
    View PubMed
  175. Love N, Meropol NJ, Ravdin PM, Bylund C, Ellis LM, Grothey A, Lenz HJ, Marshall JL, Curly SA, Paley D, Elder M. Which adjuvant systemic treatments (AdjRx) would medical oncologists (MOs) wish to receive if they had colon cancer (CCa)? A survey of 150 physicians. J Clin Oncol. 2008 May 20; 26: (15_suppl)4049.
    View PubMed
  176. Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff MF, Roach N, Sargent DJ, Tezcan H, Grothey A, Purdie DM, Sugrue MM. Initial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line. J Clin Oncol. 2008 May 20; 26: (15_suppl)15002.
    View PubMed
  177. Campbell ME, Mandrekar SJ, Hillman SL, Goldberg RM, Adjei AA, Pitot HC, Rowland KM, Grothey A, Buckner JC, Sargent DJ. What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings. J Clin Oncol. 2008 May 20; 26: (15_suppl)6520.
    View PubMed
  178. Purdie DM, Berlin JD, Flynn PJ, Grothey A, Kabbinavar FF, Kozloff MF, Dong W, Sugrue MM. The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS). J Clin Oncol. 2008 May 20; 26: (15_suppl)4103.
    View PubMed
  179. Flynn PJ, Sugrue MM, Feng S, Purdie DM, Grothey A, Sargent DJ, Berlin JD, Kabbinavar FF, Dong W, Kozloff MF. Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS). J Clin Oncol. 2008 May 20; 26: (15_suppl)4104.
    View PubMed
  180. Sugrue MM, Purdie DM, Feng S, Flynn PJ, Grothey A, Sargent DJ, Berlin JD, Kabbinavar FF, Dong W, Kozloff MF. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS). J Clin Oncol. 2008 May 20; 26: (15_suppl)4105.
    View PubMed
  181. O'Connell MJ, Campbell ME, Goldberg RM, Grothey A, Seitz JF, Benedetti JK, Andre T, Haller DG, Sargent DJ. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol. 2008 May 10; 26(14):2336-41.
    View PubMed
  182. Galanis E, Carlson SK, Foster NR, Lowe V, Quevedo F, McWilliams RR, Grothey A, Jatoi A, Alberts SR, Rubin J. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol Ther. 2008 May; 16: (5)979-84.
    View PubMed
  183. Grothey A, Ellis LM. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J. 2008 May-Jun; 14(3):170-7.
    View PubMed
  184. Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008 Jan 10; 26 (2):183-9
    View PubMed
  185. Grothey A. The role of chemotherapy in stage IV colorectal cancer: Focus on combinations with biologic agents and conversion therapy. Community Oncol. 2008; 5(6 SUPPL. 6):3-8.
    View PubMed
  186. Grothey A. Metastatic colorectal cancer: integrating recent findings into patient care. Clin Adv Hematol Oncol. 2008; 6(12, suppl 21):7-11.
  187. Grothey A, Arnold D, Ellis LM. Should bevacizumab be continued beyond progression in colorectal cancer? Current Colorectal Cancer Reports. 2008; 4(3):139-43.
  188. Arkenau HT, Graeven U, Kubicka S, Grothey A, Englisch-Fritz C, Kretzschmar A, Greil R, Freier W, Seufferlein T, Hinke A, Schmoll HJ, Schmiegel W, Porschen R, AIO Colorectal Study Group. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2008 Jan; 7(1):60-4.
    View PubMed
  189. Grothey A. Biological therapy and other novel therapies in early-stage disease: are they appropriate? Clin Cancer Res. 2007 Nov 15; 13: (22 Pt 2)6909s-12s.
    View PubMed
  190. Rosen LS, Bilchik AJ, Beart RW Jr, Benson AB 3rd, Chang KJ, Compton CC, Grothey A, Haller DG, Ko CY, Lynch PM, Nelson H, Stamos MJ, Turner RR, Willett CG. New approaches to assessing and treating early-stage colon and rectal cancer: summary statement from 2007 Santa Monica Conference. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 2):6853s-6s.
    View PubMed
  191. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Kerr D, Green E, Wieand HS, Goldberg RM, de Gramont A, ACCENT Group. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol. 2007 Oct 10; 25(29):4569-74. Epub 2007 Sep 17.
    View PubMed
  192. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, AIO Colorectal Study Group. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007 Sep 20; 25(27):4217-23. Epub 2007 Jun 04.
    View PubMed
  193. Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007 Sep; 15(9):1023-33. Epub 2007 Jan 05.
    View PubMed
  194. Ashley AC, Sargent DJ, Alberts SR, Grothey A, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer. 2007 Aug 1; 110(3):670-7.
    View PubMed
  195. Grothey A. The Continuum of Care in Colorectal Cancer: Eliminating the Concept of Distinct Lines of Treatment. ASCO. 2007 Educational Book. 2007 Jun:224-8.
  196. Grothey A, Marshall JL. Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy. Oncology (Williston Park). 2007 Apr; 21(5):553-64, 566; discussion 566-8, 577-8.
    View PubMed
  197. Loprinzi CL, Barton DL, Jatoi A, Sloan J, Martenson J, Steensma D, Rao R, Novotny P, Sood A, Grothey A, Minasian L, Windschitl H. Symptom control trials: a 20-year experience. J Support Oncol. 2007 Mar; 5(3):119-25, 128.
    View PubMed
  198. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist. 2007 Jan; 12: (1)38-50.
    View PubMed
  199. Grothey A. Is there a third-line therapy for metastatic colorectal cancer? Semin Oncol. 2006 Dec; 33(6 Suppl 11):S36-8.
    View PubMed
  200. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology (Williston Park). 2006 Dec; 20: (14 Suppl 10)21-8.
    View PubMed
  201. Tyagi P, Grothey A. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial. Clin Colorectal Cancer. 2006 Nov; 6(4):261-4.
    View PubMed
  202. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006 Oct; 13(10):1261-8. Epub 2006 Sep 01.
    View PubMed
  203. Grothey A. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. Semin Oncol. 2006 Oct; 33(5 Suppl 10):S41-9.
    View PubMed
  204. Gibson TB, Grothey A. Do all patients with metastatic colorectal cancer need chemotherapy until disease progression? Clin Colorectal Cancer. 2006 Sep; 6(3):196-201.
    View PubMed
  205. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006 Jun 20; 24(18):2903-9.
    View PubMed
  206. Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Steis R, Dong W, Suzuki S, Sugrue M, Grothey A. Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). J Clin Oncol. 2006 Jun 20; 24: (18_suppl)3537.
    View PubMed
  207. Hedrick E, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Dong W, Suzuki S, Sugrue M, Grothey A. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). J Clin Oncol. 2006 Jun 20; 24: (18_suppl)3536.
    View PubMed
  208. Sugrue M, Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn P, Steis R, Dong W, Sarkar S, Grothey A. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)3535.
    View PubMed
  209. Grothey A, Hedrick EE, Mass RD, Sarkar S, Ramanathan RK, Hurwitz H, Goldberg RM, Sargent DJ. Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC): A comparative analysis of N9741 and AVF2107. J Clin Oncol. 2006 Jun 20; 24: (18_suppl)3516.
    View PubMed
  210. Terstriep S, Grothey A. First- and second-line therapy of metastatic colorectal cancer. Expert Rev Anticancer Ther. 2006 Jun; 6(6):921-30.
    View PubMed
  211. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 May; 6(1):29-31.
    View PubMed
  212. Grothey A. Does bevacizumab improve survival in patients with metastatic colorectal cancer treated with chemotherapy? Nat Clin Pract Oncol. 2006 Jan; 3(1):22-3.
    View PubMed
  213. Grothey A. Defining the role of panitumumab in colorectal cancer. Community Oncol. 2006; 3(10 Suppl 4):10-4, 16.
    View PubMed
  214. Grothey E, Grothey A. New treatment options for patients with metastatic colorectal cancer. Community Oncol. 2006; 3(10 Suppl 4):3-9.
    View PubMed
  215. Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005 Dec 1; 23(34):8664-70.
    View PubMed
  216. Kim GP, Grothey A. Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway. Clin Colorectal Cancer. 2005 Nov; 5 Suppl 2:S89-97
    View PubMed
  217. Grothey A, Saif M. Antiangiogenesis as antitumor therapy in gastrointestinal malignancies. Integrating Antiangiogenic Molecules in the Treatment of Patients With Cancer. 2005 Oct:10-21.
    View PubMed
  218. Saif M, Grothey A. Antiangiogenesis as Antitumor Therapy in Nongastrointestinal Malignancies: Renal Cell, Lungs, and Breast. Integrating Antiangoiogenic Molecules in the Treatment of Patients With Cancer. 2005 Oct.:21-30.
    View PubMed
  219. Alberts SR, Sinicrope FA, Grothey A. N0147: a randomized phase III trial of oxaliplatin plus 5-fluorouracil/leucovorin with or without cetuximab after curative resection of stage III colon cancer. Clin Colorectal Cancer. 2005 Sep; 5 (3):211-3
    View PubMed
  220. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005 Aug; 16(8):1311-9.
    View PubMed
  221. Arkenau HT, Schmoll H, Kubicka S, Kretzschmar A, Freier W, Seufferlein T, Graeven U, Grothey A, Hinke A, Porschen R. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysis. J Clin Oncol. 2005 Jun; 23: (16_suppl)3507.
    View PubMed
  222. Grothey A, McLeod HL, Green EM, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP, Goldberg RM. Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. J Clin Oncol. 2005 Jun; 23: (16_suppl)3509.
    View PubMed
  223. Kozloff M, Cohn A, Christiansen N, Flynn P, Kabbinavar F, Robles R, Ulcickas Yood M, Sarkar S, Hambleton J, Grothey A. Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S. J Clin Oncol. 2005 Jun; 23: (16_suppl)3566.
    View PubMed
  224. Love N, Grothey A, Curley S, Ellis L, Lenz HJ, Paley M, Kaderman R, Ziel K, Paley D. Perspectives of patients with colorectal cancer (PCRC): A pilot project to determine interests in and understanding of patient education on clinical research. J Clin Oncol. 2005 Jun; 23: (16_suppl)3635.
    View PubMed
  225. Harba A, Peinert S, Grothe W, Jordan K, Kegel T, Mueller LP, Behrens R, Grothey A, Arnold D, Schmoll HJ. Weekly administration of 5-fluorouracil (5-FU), folinic acid (FA), oxaliplatin (L-OHP) and irinotecan (CPT-11) [FUFOXIRI] for patients with metastatic gastric or colorectal cancer. J Clin Oncol. 2005 Jun; 23: (16_suppl)3719.
    View PubMed
  226. Morton RF, Sloan JA, Grothey A, Sargent DJ, McLeod H, Green EM, Fuchs C, Ramanathan RK, Williamson SK, Goldberg RM. A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. J Clin Oncol. 2005 Jun; 23: (16_suppl)8087.
    View PubMed
  227. Goetz MP, Safgren S, Goldberg RM, Grothey AF, Mandrekar SJ, Reid JM, Erlichman C, Adjei AA, Rubin J, Ames MM. A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7). J Clin Oncol. 2005 Jun; 23: (16_suppl)2014.
    View PubMed
  228. Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol. 2005 May 20; 23(15):3311-3.
    View PubMed
  229. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2005 Apr 18; 2:CD004064.
    View PubMed
  230. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005 Apr; 5 Suppl 1:S38-46
    View PubMed
  231. Grothey A, Kleeberg UR, Stauch M, Hieke K. Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds. Z Gastroenterol. 2005 Feb; 43(2):155-61.
    View PubMed
  232. Jordan K, Hinke A, Grothey A, Schmoll HJ. Granisetron versus tropisetron for prophylaxis of acute chemotherpy-induced emesis: a pooled analysis. Support Care Cancer. 2005; 13:26-31.
    View PubMed
  233. Jordan K, Grothey A, Grothe W, Kegel T, Wolf HH, Schmoll HJ. Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. Eur J Haematol. 2005 Jan; 74:263-266.
    View PubMed
  234. Jordan K, Grothey A, Kegel T, Fibich C, Schobert C. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. Onkologie. 2005 Jan; 28:88-92.
    View PubMed
  235. Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ. Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics. 2005; 5 (5):317-25
    View PubMed
  236. Jackisch C, Grothey A, Schlotter CM, Mielke S, Wassmann KI, Behringer D, Mross K, Rody A. Practical aspects in the treatment of metastatic breast cancer with administration of paclitaxel weekly. Geburtsh Frauenheilk. 2004 Nov; 64(11):1199-1204.
    View PubMed
  237. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother. 2004 Oct; 5(10):2159-70.
    View PubMed
  238. Hieke K, Kleeberg UR, Stauch M, Grothey A. Costs of treatment of colorectal cancer in different settings in Germany. European Journal of Health Economics. 2004 Oct; 5(3):270-3.
    View PubMed
  239. Goetz MP, Grothey A. Developments in combination chemotherapy for colorectal cancer. Expert Rev Anticancer Ther. 2004 Aug; 4 (4):627-37
    View PubMed
  240. Jordan K, Hinke A, Grothey A, Schmoll HJ. A meta-analysis comparing the efficacy of five 5-HT3-receptor antagonists (5-HT3-RAs) for acute chemotherapy induced emesis. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)8048.
    View PubMed
  241. Hedrick EE, Hurwitz H, Sarkar S, Griffing S, Novotny W, Grothey A. Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC). J Clin Oncol. 2004 Jul 15; 22: (14_suppl)3517.
    View PubMed
  242. Grothey A, Jordan K, Kellner O, Constantin C, Dietrich G, Kroening H, Mantovani L, Schlichting C, Forstbauer H, Schmoll HJ. Capecitabine/ irinotecan (CapIri) and capecitabine/oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: Results of a randomized phase II study. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)3534.
    View PubMed
  243. Arkenau HT, Schmoll H, Kubicka S, Seufferlein T, Reichardt P, Freier W, Graeven U, Grothey A, Porschen R. Phase III trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment in advanced colorectal carcinoma (ACRC): Results of an interim safety analysis. J Clin Oncol. 2004 Jul 15; 22: (14_suppl)3546.
    View PubMed
  244. Grothey A, Goetz MP. Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. Clin Colorectal Cancer. 2004 Jun; 4 Suppl 1:S37-42
    View PubMed
  245. Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A. Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers. Clin Colorectal Cancer. 2004 May; 4(1):46-50.
    View PubMed
  246. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004 Apr 1; 22 (7):1209-14
    View PubMed
  247. Marse H, Van Cutsem E, Grothey A, Valverde S. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda((R))). Eur J Oncol Nurs. 2004; 8(3 Suppl):S16-30.
    View PubMed
  248. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003 Aug; 30(4 Suppl 15):5-13.
    View PubMed
  249. Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res. 2003 Jan 15; 63(2):513-21.
    View PubMed
  250. Grothey A, Arnold D. Highlights in colorectal cancer. Onkologie heute. 2003; 1(2):10-4.
    View PubMed
  251. Grothey A, Jordan K. Capecitabine/ oxaliplatin as first-line therapy in colorectal cancer - a case report. Case Studies in Colorectal Cancer. 2003; 2(3):1-8.
    View PubMed
  252. Grothey A, Kellermann L, Schmoll HJ. [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms] [German]. Med Klin. 2002 May 15; 97(5):270-7.
    View PubMed
  253. Voigt W, Behrmann C, Schlueter A, Kegel T, Grothey A, Schmoll HJ. A new chemoembolization protocol in refractory liver metastasis of colorectal cancer--a feasibility study. Onkologie. 2002 Apr; 25(2):158-64.
    View PubMed
  254. Grothey A, Graeven U. Colorectal cancer - new trials - new developments. Journal Med. 2002; 3:21-4.
    View PubMed
  255. Grothey A, Graeven U. New developments in the treatment of advanced colorectal cancer. Journal Onkologie. 2002; 2(3):26-30.
    View PubMed
  256. Grothey A, Dempke W. Current status of bisphoshonates in hematology and oncology. Internist prax. 2002; 42:291-9.
    View PubMed
  257. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol. 2001 Jul; 127(7):411-7.
    View PubMed
  258. Grothey A, Schmoll HJ. New chemotherapy approaches in colorectal cancer. Curr Opin Oncol. 2001 Jul; 13(4):275-86.
    View PubMed
  259. Kohne CH, Grothey A, Bokemeyer C, Bontke N, Aapro M. Chemotherapy in elderly patients with colorectal cancer. Ann Oncol. 2001 Apr; 12(4):435-42.
    View PubMed
  260. Fittkau M, Grothey A, Gerlach R, Schmoll HJ. A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. J Cancer Res Clin Oncol. 2001 Feb; 127(2):96-100.
    View PubMed
  261. Koehne C, Grothey A, et al. Chemotherapy of the elderly patient with colorectal cancer. Arzneimitteltherapie. 2001; 19:377-85.
    View PubMed
  262. Grothey A. Combination therapy with very good results in a phase III study in colorectal cancer. MedReview. 2001; 2:16-7.
    View PubMed
  263. Grothey A. Prognostic and predictive factors in colorectal cancer. Journal Onkologie. 2001; 1:22-3.
    View PubMed
  264. Grothey A. First-line therapy of advanced colorectal cancer. Journal Onkologie. 2001; 1:12-7.
    View PubMed
  265. Grothey A. A typical cancer of the elderly - the colorectal carcinoma. Forum (Genova). 2001; 16: (5)42-7.
    View PubMed
  266. Dempke W, Von Poblozki A, Grothey A, Schmoll HJ. Human hematopoietic growth factors: old lessons and new perspectives. Anticancer Res. 2000 Nov-Dec; 20(6D):5155-64.
    View PubMed
  267. Grothey A, Hashizume R, Ji H, Tubb BE, Patrick CW Jr, Yu D, Mooney EE, McCrea PD. C-erbB-2/ HER-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines. Oncogene. 2000 Oct 5; 19(42):4864-75.
    View PubMed
  268. Grothey A, Hashizume R, Sahin AA, McCrea PD. Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer. 2000 Oct; 83(7):870-3.
    View PubMed
  269. Hasenburg A, Grothey A, Jaspers V, Gitsch G, Spatling L. Breast size as risk factor for tumor size at diagnosis. Anticancer Res. 2000 May-Jun; 20(3B):2041-4.
    View PubMed
  270. Voigt W, Bulankin A, Muller T, Schoeber C, Grothey A, Hoang-Vu C, Schmoll HJ. Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res. 2000 May; 6(5):2087-93.
    View PubMed
  271. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ. Cisplatin resistance and oncogenes--a review. Anticancer Drugs. 2000 Apr; 11(4):225-36.
    View PubMed
  272. Kleber G, Grothey A. Hepatocellular carcinoma - epidemiology, laboratory, and prognosis. Onkologe. 2000; 6:292-300.
    View PubMed
  273. Grothey A, Schmoll HJ. Systemic therapy of hepatocellular carcinoma. Onkologe. 2000; 6:327-35.
    View PubMed
  274. Buechele T, Grothey A, et al. New perspectives with new cytostatic drugs in colorectal cancer. Onkologe. 2000; 6:410-9.
    View PubMed
  275. Dempke W, Behrmann C, Schober C, Buchele T, Grothey A, Schmoll HJ. [Diagnostic and therapeutic management of the superior vena cava syndrome] [German]. Med Klin. 1999 Dec 15; 94(12):681-4.
    View PubMed
  276. Schmoll HJ, Buchele T, Grothey A, Dempke W. Where do we stand with 5-fluorouracil? Semin Oncol. 1999 Dec; 26(6):589-605.
    View PubMed
  277. Dempke W, Voigt W, Grothey A, Schmoll HJ. Preferential repair of the N-ras gene in K 562 cells after exposure to cisplatin. Anticancer Drugs. 1999 Jul; 10(6):545-9.
    View PubMed
  278. Akimoto T, Kawabe S, Grothey A, Milas L. Low E-cadherin and beta-catenin expression correlates with increased spontaneous and artificial lung metastases of murine carcinomas. Clin Exp Metastasis. 1999 Mar; 17(2):171-6.
    View PubMed
  279. Dempke W, Voigt W, Grothey A, Schmoll HJ. Option for high-dose chemotherapy in advanced gynecologic cancers. Gyn. 1999; 4:368-375.
  280. Grothey A, Voigt W, Schober C, Muller T, Dempke W, Schmoll HJ. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol. 1999; 125(3-4):166-73.
    View PubMed
  281. Buechele T, Grothey A, et al. New drugs in the treatment of colorectal cancer. Medizin im Bild. 1999; 2:50-5.
    View PubMed
  282. Buechele T, Grothey A, et al. Adjuvant and palliative therapy of colorectal cancer. Spektrum Onkologie. 1999; 3:3-23.
    View PubMed
  283. Grothey A, Duppe J, Hasenburg A, Voigtmann R. [Use of alternative medicine in oncology patients] [German]. Dtsch Med Wochenschr. 1998 Jul 31; 123(31-32):923-9.
    View PubMed
  284. Kudelka AP, Hasenburg A, Verschraegen CF, Edwards CL, Meyers CA, Varma D, Freedman RS, Forman A, Conrad CA, Grove W, Grothey A, Kavanagh JJ. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma. Anticancer Drugs. 1998 Jun; 9(5):405-9.
    View PubMed
  285. Grothey A, Heistermann P, Philippou S, Voigtmann R. Serum levels of soluble intercellular adhesion molecule-1 (ICAM-1, CD54) in patients with non-small-cell lung cancer: correlation with histological expression of ICAM-1 and tumour stage. Br J Cancer. 1998 Mar; 77(5):801-7.
    View PubMed
  286. Hasenburg A, Grothey A, et al. Current studies on cervical cancer in the USA. Onkologe. 1998; 4:180-4.
    View PubMed
  287. Sanner B, Horstmann E, Heinze P, Kopp J, Grothey A. Successful rt-PA lysis of a transit thrombus in the right ventricle. Intensivmed. 1994; 31:447-451.
  288. Hasenburg A, Grothey A, et al. Clinical course and prognosis of patients under artificial respiration. Herz Kreislauf. 1992; 24:127-31.
    View PubMed
  289. Donhuijsen K, Grothey A, Volker B, Dermoumi H. [Zygomycoses: clinical aspects and pathology in 10 patients] [German]. Schweiz Med Wochenschr. 1991 Oct 12; 121(41):1493-8.
    View PubMed
  290. Grothey A, Donhuijsen K. [Mucoraceae mycoses: clinical aspects and pathology in ten patients]. [German]. Mycoses. 1991; 34 Suppl 1:29-32.
    View PubMed
  291. Hoffken K, Overkamp F, Stirbu J, Grothey A, Flasshove M, Hoelzer D, Ganser A. Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study. Onkologie. 1990 Feb; 13(1):33-7.
    View PubMed
  292. Franke I, Grothey A, Koch S, Witteler FJ, Binder M, Sandermann H Jr. N-Ethyl-17(R,S)-methyl-(6aR,10aR)-delta 8-tetrahydrocannabinol-18-oic amide. Brain pharmacokinetics in mice, triglyceride/phospholipid partitioning and generalization to the discriminative stimulus properties of delta 9-THC in rats. Biochem Pharmacol. 1985 Nov 15; 34(22):3983-6.
    View PubMed